While direct presentation of tumor antigens on MHCI by tumor cells plays a pivotal role in effector function of CD8+ T cells, cross-presentation by professional APCs is required to prime naive CD8+ T cells and to sustain cytotoxic immune responses [2]. This evidence concerns the gene CD8A and neoplasm.